cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biovie Inc
3 own
3 watching
Current Price
$5.67
$-0.11
(-1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
174.43M
52-Week High
52-Week High
14.38
52-Week Low
52-Week Low
1.325
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization174.43M
icon52-Week High14.38
icon52-Week Low1.325
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Biovie Inc do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer s disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
Read More
How much money does Biovie Inc make?
News & Events about Biovie Inc.
Accesswire
2 months ago
ORLANDO, FL / ACCESSWIRE / March 24, 2023 / RedChip Companies will air new interviews with BioVie Inc. (NASDAQ:BIVI) and iRemedy on The RedChip Money Report® on Bloomberg TV, this Saturday, March 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes...
Globe Newswire
2 months ago
CARSON CITY, Nev., March 21, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disordersand advanced liver disease,today announceddata from its Phase 2 ...
Globe Newswire
2 months ago
Patients treated with BIV201 experienced reduced ascites fluid buildup (pCARSON CITY, Nev., March 13, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (BioVie or the Company) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative ...
Globe Newswire
3 months ago
CARSON CITY, Nev., March 09, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (BioVie or the Company), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disordersand advanced liver disease,today announced the participation of its...
Globe Newswire
3 months ago
6 out of 20 patients treated with NE3107 experienced a morning on state while 0 out of 19 placebo-treated patients had an on (p=0.02) Day 28 Improvement in Motor Controls vs. Day 0 Day 28 Improvement in Motor Controls vs. Day 0 CARSON CITY, Nev., March 06, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (...
Frequently Asked Questions
Frequently Asked Questions
What is Biovie Inc share price today?
plus_minus_icon
Can Indians buy Biovie Inc shares?
plus_minus_icon
How can I buy Biovie Inc shares from India?
plus_minus_icon
Can Fractional shares of Biovie Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biovie Inc stocks?
plus_minus_icon
What is today’s traded volume of Biovie Inc?
plus_minus_icon
What is today’s market capitalisation of Biovie Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biovie Inc?
plus_minus_icon
What percentage is Biovie Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biovie Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$5.67
$-0.11
(-1.9%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00